We hypothesized that targeting MDSCs by inhibiting the CSF-1R axis could hinder the M-MSDCs recruitment and activate the immunity in the tumor microenvironment when combined with BNCT, leading to a synergistic effect for better tumor control. The gene discussed is CSF1R; the disease is neoplasm.